Vicuron (NASDAQ:MICU)
Historical Stock Chart
From Jul 2019 to Jul 2024
Vicuron Pharmaceuticals Appoints Alan W. Dunton, M.D., to Board
of Directors
KING OF PRUSSIA, Pa., Sept. 20 /PRNewswire-FirstCall/ -- Vicuron
Pharmaceuticals Inc. (Nasdaq: MICU; Nuovo Mercato) today announced that the
company appointed Alan W. Dunton, M.D. to its board of directors.
"We are excited to have someone of Alan's stature and consistent accomplishment
on our board," said George F. Horner, III, President and CEO of Vicuron. "He
has decades of experience developing some of the top-selling drugs in the
industry, including a major community antibiotic, and leads a private
clinical-stage biopharmaceutical company of his own. His world-class clinical
development track record, in-depth commercial knowledge and pipeline-building
capability will be of substantial value as we develop and seek to commercialize
our own promising pipeline of antimicrobial agents."
Dr. Dunton is a recognized leader in drug development and clinical research.
His 20 years of experience have been marked by the development and approval of
the prescription drugs Levaquin(R), Topamax(R), Reminyl(R), Regranex(R),
Risperdal(R) as well as the successful OTC product, Aleve(R). He was named
President and Chief Executive Officer of MetaPhore Pharmaceuticals, Inc., a
private biopharmaceutical company, in February 2003.
Prior to MetaPhore, Dr. Dunton held numerous leadership positions, including
President and Chief Operating Officer of Emisphere Technologies, Inc.;
President and Managing Director of the Janssen Research Foundation, a Johnson &
Johnson company; and executive positions at Roche, CIBA-GEIGY (now Novartis),
and Syntex.
Dr. Dunton received his Medical Degree from New York University School of
Medicine in 1980 and completed his post-graduate training in Internal Medicine
at the New York University Medical Center/Bellevue Hospital VA Medical Center,
and a fellowship in Clinical Pharmacology at Cornell University/Medical
College/New York Hospital.
About Vicuron
Vicuron Pharmaceuticals is a biopharmaceutical company focused on discovering,
developing, manufacturing and commercializing vital medicine for seriously ill
patients. In May 2004, Vicuron received an approvable letter from the FDA for
its lead product anidulafungin for the treatment of esophageal candidiasis.
The company's other lead product, dalbavancin, a novel intravenous antibiotic
for the treatment of serious Gram-positive infections, has completed Phase III
clinical trials. The company's versatile research engine integrates
industry-leading expertise in functional genomics, natural products discovery,
mechanism-based drug design and combinatorial and medicinal chemistry. These
approaches are yielding promising novel and next- generation compounds, many of
which are in the later stages of preclinical development. In addition, the
company has research and development collaborations with leading pharmaceutical
companies, such as Pfizer and Novartis.
Forward-Looking Statements
This news release contains forward-looking statements that predict or describe
future events or trends. The matters described in these forward-looking
statements are subject to known and unknown risks, uncertainties and other
unpredictable factors, many of which are beyond Vicuron's control. Vicuron
faces many risks that could cause its actual performance to differ materially
from the results predicted by its forward-looking statements, including the
possibilities that clinical trials and the results thereof might be delayed,
that the timing of the filing of any new drug application might be delayed,
that subsequent clinical trials might indicate that a product candidate is
unsafe or ineffective, that any filed new drug application may not be approved
by the FDA, that ongoing proprietary and collaborative research might not occur
or yield useful results, that a third party may not be willing to license our
product candidates on terms acceptable to us or at all, that competitors might
develop superior substitutes for their products or market them more
effectively, that a sales force may not be developed as contemplated and that
one or more of its product candidates may not be commercialized successfully.
The reports that Vicuron files with the U.S. Securities and Exchange Commission
contain a fuller description of these and many other risks to which Vicuron is
subject. Because of those risks, Vicuron's actual results, performance or
achievements may differ materially from the results, performance or
achievements contemplated by its forward-looking statement. The information set
forth in this news release represents management's current expectations and
intentions. Vicuron assumes no responsibility to issue updates to the
forward-looking matters discussed in this news release.
DATASOURCE: Vicuron Pharmaceuticals Inc.
CONTACT: Dov A. Goldstein, M.D. of Vicuron Pharmaceuticals Inc.,
+1-610-205-2312, or ; or Hala Bashir of WeissComm
Partners, +1-212-204-2080, or , or Aline Schimmel of
Burns McClellan Inc., +1-212-213-0006, or , both for
Vicuron Pharmaceuticals Inc.
Web site: http://www.vicuron.com/